According to the 2023 American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) guidelines for HER2 testing, HER2-enriched breast cancer is divided into three subgroups based on immunohistochemistry (IHC) and in situ hybridization (ISH) results. This evidence concerns the gene ERBB2 and breast cancer.